[1]张 铭,张娜娜,余 信,等.达格列净对大鼠心肌缺血再灌注损伤保护的实验研究[J].陕西医学杂志,2022,51(7):795-798.[doi:DOI:10.3969/j.issn.1000-7377.2022.07.006]
　ZHANG Ming,ZHANG Nana,YU Xin,et al.Protective effect of dapagliflozin on myocardial ischemia-reperfusion injury in rats[J].,2022,51(7):795-798.[doi:DOI:10.3969/j.issn.1000-7377.2022.07.006]
点击复制

达格列净对大鼠心肌缺血再灌注损伤保护的实验研究
分享到：

《陕西医学杂志》[ISSN:1000-7377/CN:61-1281/TN]

卷:
51
期数:
2022年7期
页码:
795-798
栏目:
基础研究
出版日期:
2022-07-05

文章信息/Info

Title:
Protective effect of dapagliflozin on myocardial ischemia-reperfusion injury in rats
作者:
张 铭1; 张娜娜1; 余 信1; 周国琼1; 李 静2
(1.西安交通大学医学院附属红会医院,陕西 西安710054; 2.陕西省人民医院中医科,陕西 西安710068)
Author(s):
ZHANG Ming; ZHANG Nana; YU Xin; ZHOU Guoqiong; LI Jing
(Honghui Hospital Affiliated to Medical Department of Xi'an Jiaotong University,Xi'an 710054,China)
关键词:
心肌缺血;  再灌注损伤;  心功能;  钠-葡萄糖共转运蛋白2抑制剂;  达格列净;  大鼠
Keywords:
Myocardial ischemia;  Reperfusion injury;  Cardiac function;  Sodium-glucose cotransporter 2 inhibitor;  Dapagliflozin;  Rat
分类号:
R 541
DOI:
DOI:10.3969/j.issn.1000-7377.2022.07.006
文献标志码:
A
摘要:
目的:通过心肌缺血再灌注损伤(I/R)的不同时间点急性给药达格列净,探讨钠-葡萄糖共转运蛋白2(SGLT-2)抑制剂对心功能的影响。 方法:对40只大鼠进行同等程度的心脏I/R刺激。将大鼠分为四个干预组:对照组、预处理组、缺血组、再灌注开始时组,快速给予SGLT-2抑制剂(达格列净,1 mg/kg)。监测各组大鼠心肌梗死面积大小、左室功能和心律失常情况。结果:缺血前给予达格列净可降低心律失常发生的频率、减小心肌梗死面积,使心肌I/R损伤后左室功能得到改善,从而达到最大程度的心脏保护作用。缺血期间给予达格列净也显示出心脏保护作用,但效果较缺血前给药降低。结论:心脏I/R损伤时急性给药达格列净可通过减少心肌梗死面积、改善左室功能和减少心律失常而发挥心脏保护作用。
Abstract:
Objective:To investigate the effect of sodium-glucose cotransporter 2(SGLT-2)inhibitor on cardiac function by acute administration of dapagliflozin at different time points during myocardial ischemia-reperfusion(I/R)injury.Methods:Forty rats were subjected to the same degree of cardiac I/R stimulation.The rats were divided into 4 intervention groups:control group,preconditioning group,ischemia group,and reperfusion initiation group,and were rapidly given 1 mg/kg of dapagliflozin.The size of myocardial infarction,left ventricular function and arrhythmia in each group were monitored.Results:The administration of dapagliflozin before ischemia could reduce the frequency of arrhythmia and the area of myocardial infarction,and improve the left ventricular function after myocardial I/R injury,thus achieving the greatest degree of cardiac protection.The administration of dapagliflozin during ischemia also showed a cardioprotective effect,but the effect was lower than that before ischemia.Conclusion:Acute administration of dapagliflozin in patients with myocardial I/R injury can play a cardioprotective role by reducing the size of myocardial infarction,improving left ventricular function and reducing arrhythmia.

参考文献/References:

[1] Wong ND.Epidemiological studies of CHD and the evolution of preventivecardiology[J].Nat Rev Cardiol,2014,11(5):276-289.
[2] Kones R.Primary prevention of coronary heart disease:Integration of new data,evolving views,revised goals,and role of rosuvastatin in management:A comprehensive survey[J].Drug Des Devel Ther,2011,8(5):325-380.
[3] Lai HM,Holtzman D,Aronow WS,et al.Association of coronary artery calcium with severity of myocardial ischemia in left anterior descending,left circumflex,and right coronary artry territories[J].Clin Cardiol,2012,35(1):61-63.
[4] Knot J,Widimsky P,Wijns W,et al.How to set up an effective national primary angioplasty network:Lessons learned from five European countries[J].EuroIntervention,2009,5(3):301-309.
[5] Danchin N.Systems of care for ST-segment elevation myocardial infarction:Impact of different models on clinical outcomes[J].JACC CardiovascInterv,2009,2(10):901-908.
[6] Cairns JA,Hirsh J,Lewis HD,et al.Antithrombotic agents in coronary artery disease[J].Chest,1992,102(4):s456-s481.
[7] Rhydwen GR,Charman S,Schofield PM.Influence of thrombolytic therapy on the patterns of ventricular septal rupture after acute myocardial infarction[J].Postgrad Med J,2002,78(921):408-412.
[8] Hausenloy DJ,Yellon DM.Myocardial ischemia-reperfusion injury:A neglected therapeutic target[J].J Clin Ivest,2013,123(1):92-100.
[9] Wanner C,Inzucchi SE,Lachin JM,et al.Empagliflozin and progression of kidney disease in type 2 diabetes[J].N Engl J Med,2016,375(4):323-334.
[10] Mc-Guire DK,Zinman B,Inzucchi SE,et al.Effects of empagliflozin on first and recurrent clinical events in patients with type 2 diabetes and atherosclerotic cardiovascular disease:A secondary analysis of the EMPA-REG outcome trial[J].Lancet Diabetes Endocrinol,2020,8(12):949-959.
[11] Lahnwong S,Palee S,Apaijai N,et al.Acute dapagliflozin administration exerts cardioprotective effects in rats with cardiac ischemia/reperfusion injury[J].Cardiovasc Diabetol,2020,19(1):1-13.
[12] Lee TM,Chang NC,Lin SZ.Dapagliflozin,a selective SGLT2 Inhibitor,attenuated cardiac fibrosis by regulating the macrophage polarizationvia STAT3 signaling in infarcted rat hearts[J].Free Radic Biol Med,2017,104(4):298-310.
[13] Lin CC,Chen SY,Lien HY,et al.Targeting the PI3K/STAT3 axis modulates age-related differences in macrophage phenotype in rats with myocardial infarction[J].J Cell Mol Med,2019,23(9):6378-6392.
[14] Thummasorn S,Shinlapawittayatorn K,Chattipakorn SC,et al.High-dose humanin analogue applied during ischemia exerts cardioprotection against ischemia/reperfusion injury by reducing mitochondrial dysfunction[J].Cardiovasc Ther,2017,35(5):e12289.
[15] Curtis MJ,Hancox JC,Farkas A,et al.The lambeth conventions(Ⅱ):Guidelines for the study of animal andhuman ventricular and supraventricular arrhythmias[J].Pharmacol and Ther,2013,139(2):213-248.
[16] Schernthaner G,Schernthaner-Reiter MH,Schernthaner GH.EMPA-REG and other cardiovascular outcome trials of glucose-lowering agents:Implications for future treatment strategies in type 2 diabetes mellitus[J].Clin Ther,2016,38(6):1288-1298.
[17] Levine MJ.Empagliflozin for type 2 diabetes mellitus:an overview of phase 3 clinical trials[J].Curr Diabetes Rev,2017,13(4):405-423.
[18] 赵 莉,李 智.达格列净干预对急性心肌梗死合并2型糖尿病患者经皮冠状动脉介入术后心室重构、心肌微灌注的影响[J].陕西医学杂志,2022,51(1):81-83.
[19] 武卫党,石 磊,张丹凤,等.达格列净对糖尿病心肌缺血大鼠心肌功能改善作用的实验研究[J].陕西医学杂志,2020,49(7):778-780.
[20] Abdul-Ghani M,Del-Prato S,Chilton R,et al.SGLT2 inhibitors and cardiovascular risk Lessons learned from the EMPA-REG outcome study[J].Diabetes Care,2016,39(5):717-725.
[21] Liu ZH,Ma XX.Impact of sodium glucose cotransporter 2(SGLT2)inhibitors on atherosclerosis:From pharmacology to pre-clinical and clinical therapeutics[J].Theranostics,2021,11(9):4502-4515.
[22] Andrew MCG,Michael F,Neil M,et al.Sodium-Glucose Co-transporter 2(SGLT2)inhibitor:Comparing trial data and real-world use[J].Diabetes Ther,2017,8(2):365-376.

相似文献/References:

[1]武卫党,郭继文△,张丹凤,等.五味子乙素改善糖酵解反应大鼠心肌缺血再灌注损伤实验研究*[J].陕西医学杂志,2020,49(1):12.
　WU Weidang,GUO Jiwen,ZHANG Danfeng,et al.Schisandrin B improves myocardial ischemiareperfusion injury by improving glycolysis[J].,2020,49(7):12.
[2]邹田田,李艾芳,杨 欢,等.上调缺氧诱导因子对老龄小鼠心肌缺血再灌注损伤保护作用的实验研究[J].陕西医学杂志,2024,(4):439.[doi:DOI:10.3969/j.issn.1000-7377.2024.04.002]
　ZOU Tiantian,LI Aifang,YANG Huan,et al.Protective mechanism of upregulating HIF on myocardial ischemia-reperfusion injury in elderly mice[J].,2024,(7):439.[doi:DOI:10.3969/j.issn.1000-7377.2024.04.002]

更新日期/Last Update: 2022-07-05